Prognostic utility of the Perugini grading of 99m Tc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid

European Heart Journal Cardiovascular Imaging

Volumn 18, Issue 12, 2017, Pages 1344-1350

  Hutt, David F ^a   Fontana, Marianna ^a   Burniston, Maria ^b   Quigley, Ann Marie ^b   Petrie, Aviva ^c   Ross, James C ^a   Page, Joanne ^a   Martinez Naharro, Ana ^a   Wechalekar, Ashutosh D ^a   Lachmann, Helen J ^a   Quarta, Candida C ^a   Rezk, Tamer ^a   Mahmood, Shameem ^a   Sachchithanantham, Sajitha ^a   Youngstein, Taryn ^a   Whelan, Carol J ^a   Lane, Thirusha ^a   Gilbertson, Janet A ^a   Rowczenio, Dorota ^a   Hawkins, Philip N ^a   Gillmore, Julian D ^a   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

99mTc DPD; ATTR amyloidosis; Perugini grade; prognosis; skeletal muscle; soft tissue

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; AGED; AMYLOIDOSIS; CINE MAGNETIC RESONANCE IMAGING; COHORT ANALYSIS; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; HEART DISEASE; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY-COMPUTED TOMOGRAPHY; SKELETAL MUSCLE; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID NEUROPATHIES, FAMILIAL; AMYLOIDOSIS; COHORT STUDIES; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY COMPUTED TOMOGRAPHY; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TECHNETIUM TC 99M SESTAMIBI; YOUNG ADULT;

EID: 85018808535     PISSN: 20472404     EISSN: 20472412     Source Type: Journal    
DOI: 10.1093/ehjci/jew325     Document Type: Article

References (21)

1. Benson MD. The hereditary amyloidoses. Best Pract Res Clin Rheumatol 2003;17:909-27.
2. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012;126:1286-300.
3. Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2013;2:e000098.
4. Maurer MS. Noninvasive identification of ATTRwt cardiac amyloid: The reemergence of nuclear cardiology. Am J Med 2015;128:1275-80.
5. Jacobson DR, Pastore R, Pool S, Malendowicz S, Kane I, Shivji A et al. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 1996;98:236-8.
6. Reilly MM, Staunton H, Harding AE. Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: A clinical, genetic, and epidemiological study. J Neurol Neurosurg Psychiatr 1995;59:45-9.
7. Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 2008;216:253-61.
8. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133: 2404-12.
9. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84.
10. Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD et al. Systemic amyloidosis in England: An epidemiological study. Br J Haematol 2013;161:525-32.
11. Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D et al. Utility and limitations of 3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging 2014;15:1289-98.
12. Falk RH, Quarta CC, Dorbala S. How to image cardiac amyloidosis. Circ Cardiovasc Imaging 2014;7:552-62.
13. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005;79:319-28.
14. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-93.
15. Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2015;132:1570-9.
16. Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. J Histochem Cytochem 1962;10:355-64.
17. Tennent GA, Cafferty KD, Pepys MB, Hawkins PN. Congo red overlay immunohistochemistry aids classification of amyloid deposits. In: RA Kyle, MA Gertz, eds. Amyloid and Amyloidosis 1998. Pearl River, New York: Parthenon Publishing; 1999. p. 160-2.
18. Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R et al. Multicenter study of planar Technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol 2016;1:880-9.
19. Carr AS, Pelayo-Negro AL, Jaunmuktane Z, Scalco RS, Hutt D, Evans MR et al. Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy. Neuromuscul Disord 2015;25:511-5.
20. Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SD, Pinney JH, Stangou AJ et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 2012;33:1120-7.
21. Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M et al. Transthyretin-related amyloidoses and the heart: A clinical overview. Nat Rev Cardiol 2010;7:398-408.